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Background
Systemic juvenile idiopathic arthritis (s-JIA) is a subtype
of chronic childhood arthritis of unknown etiology. The
anti-IL-6 receptor monoclonal antibody, tocilizumab
(TCZ), was developed, and we investigated the safety
and efficacy of TCZ in children with this disorder.
Aim
Growth analysis during the study was performed.
Methods
Forty-five s-JIA patients (17 boys and 28 girls, 8.1±4.2
years of age, disease duration 4.1±3.2 years) who com-
pleted 144 visit (ca. 3 years) of phase-III study of TCZ
were enrolled. The study had 6 week open-label phase
(8mg/kh q2W) followed by 12 week randomized, dou-
ble-blind withdrawal phase (8mg/kg q2w or placebo
q2w).
Mean standard deviation score (SDS) for height,
changes in SDS from baseline (⊿SDS), correlation
between ⊿SDS and several factors such as age, gender,
disease duration, corticosteroid dose exposure during
the study, JIA core set response were evaluated. SDS for
height calculated against the growth curve for Japanese
population was used growth analysis.
Results
Thirty-eight of 45 (84.4%) obtained clinical response at
week 144. The mean baseline SDS-height was -2.67
±1.97 and clearly showed growth impairment. Clear
inverse correlation between baseline SDS-height and dis-
ease duration was recognized. There was no clear corre-
lation between baseline corticosteroid dose and SDS-
height. ⊿SDS at week 144 was 0.04±1.06, showing varied
individual changes (⊿SDS:<-0.5 (n=10, mean 7.7 years) ,
⊿SDS:-0.5≤, <0.5 (n=21, mean 8.1 years) ⊿SDS:0.5≤
(n=14, mean 8.2 years)). Patients with less corticosteroid
exposure showed significant improvement in ⊿SDS
compared with those with higher corticosteroid expo-
sure during the study (average daily PSL equivalent dose
<6.7 mg/body, (n=22) vs. ≥6.7 mg/body (n=23),
p=0.001).
Conclusion
Growth impairments evidenced by SDS-height were
more prominent in patients with longer standing dis-
ease, which means importance of earlier intervention in
the disease course. Catch up growth was observed in
patients who required less or no corticosteroid during
TCZ treatment for 3 years.
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